Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.87)
# 1,576
Out of 5,148 analysts
46
Total ratings
40%
Success rate
55.59%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics | Initiates: Buy | $2.5 | $0.66 | +278.21% | 1 | Jan 23, 2026 | |
| NXTC NextCure | Upgrades: Buy | $18 | $12.52 | +43.77% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $13.88 | +8.07% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $1.94 | +879.38% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $13.52 | +121.89% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.08 | +1,937.04% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $9.06 | +164.90% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $14.20 | +780.28% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $3.37 | +434.12% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $2.25 | +746.33% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.19 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $150.15 | -47.27% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $103.35 | +49.98% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $29.81 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.14 | +696.18% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $3.23 | +55,627.55% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $35.36 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.53 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.97 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $2.99 | +50,067.22% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.14 | +78,847.37% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $10.11 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $11.20 | +1,373.21% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $5.01 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.02 | - | 2 | Jan 4, 2017 |
Decoy Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $2.5
Current: $0.66
Upside: +278.21%
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $12.52
Upside: +43.77%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $13.88
Upside: +8.07%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $1.94
Upside: +879.38%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $13.52
Upside: +121.89%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.08
Upside: +1,937.04%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $9.06
Upside: +164.90%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $14.20
Upside: +780.28%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $3.37
Upside: +434.12%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $2.25
Upside: +746.33%
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.19
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $150.15
Upside: -47.27%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $103.35
Upside: +49.98%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $29.81
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.14
Upside: +696.18%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $3.23
Upside: +55,627.55%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $35.36
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.53
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $4.97
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $2.99
Upside: +50,067.22%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.14
Upside: +78,847.37%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $10.11
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $11.20
Upside: +1,373.21%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $5.01
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.02
Upside: -